What ISRG Investors Need to Know After a Strong Day of Trading

We're taking a closer look at Intuitive Surgical, whose shares moved 3.9% compared to 0.5% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.

  • ISRG has an average analyst rating of buy and is -25.5% away from its mean target price of $255.2 per share

  • Its trailing 12 month price to earnings (Eps) is $9.72 per share

  • Intuitive Surgical, has a trailing 12 month Price to Earnings (P/E) ratio of 19.6 while the S&P 500 average is 15.97

  • Its forward 12 month price to earnings (Eps) is $9.72 per share and its forward P/E ratio is 12.0

  • ISRG has a Price to Earnings Growth ratio of 7.74, which shows the company is potentially overvalued when we factor growth into the price to earnings calculus.

  • The company has a Price to Book (P/B) ratio of 2.2 in contrast to the S&P 500's average ratio of 2.95

  • Intuitive Surgical, is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07

  • Intuitive Surgical, has on average reported free cash flows of $1,258,500,000.00 over the last four years, during which time they have grown by an an average of 22.9%

  • ISRG's gross profit margins have averaged 68.6 % over the last four years, during which time they had a growth rate of -0.2 % and a coefficient of variability of 2.9 %.

At Market Interference, we believe in giving retail investors access to timely and accurate data to help inform their investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.